medicines

If you are among those people who are toiling hard to bring back your life on track after the pandemic blow, If you are trying to provide for your family cutting on your expenses, trying to give a good education to your child and somehow manage the rising school/ college fees, you are trying to take care of your parents, pay the bills in the house and then save a little bit for yourself, your future, maybe planning to buy a house for yourself, or a vehicle... Well, come out of your dreamland and face the reality. Sorry to say, but I've got a very bad news for you. The IPL might be starting from today, but the fuel prices have already crossed century and catching up with the trend is LPG, Essential commodities and now the medicines. Generally, during March-April people wait for promotion, slaary hike. But the govt has taken this concept very seriously and generalized it to hike the prices of the goods and services that directly impact your pocket. Now your salary may or may not have risen, but you have to pay extra from your pocket. According to reports, Prices of essential medicines including painkillers, antibiotics, anti-infective are set to go up from April. The government has allowed an increase of over 10 percent for the scheduled drugs. What this decision means and What impact will this have on your overall budget? Arti Ghargi, Akhilesh Bhargava and Sujit Nair discuss in this podcast. 

DLA Piper's Jim Greenwood and Geoff Levitt are joined by Peter Kolchinsky, founding Partner and Portfolio Manager at RA Capital, to discuss the importance of – and complications in – balancing biopharmaceutical innovation, industry regulations and prescription drug availability.

See omnystudio.com/listener for privacy information.

Don't forget to rate us on Spotify and Apple Podcasts!

Tweet to Karthik Nagarajan (@The_Karthik): https://twitter.com/The_Karthik and follow his WordPress handle here (filterkoffee.com).

You can listen to this show and other awesome shows on the IVM Podcasts app on Android: https://ivm.today/android or iOS: https://ivm.today/ios, or any other podcast app.

You can check out our website at http://www.ivmpodcasts.com

See omnystudio.com/listener for privacy information.

In this special bonus episode, Adam Rutherford explores a different aspect of gene therapy - how do you actually make one? Expert guests discuss the highly complex task of scaling-up manufacturing from the small amounts needed for research, to creating batches big enough for clinical and commercial scale. And once that hurdle has been cleared, how do they address the additional challenge of storing and transporting the medicine at ultra-low temperatures?

Featuring guests:
Bert Bruce, Regional President, North America, Rare Disease, Pfizer
Bob Smith, Senior Vice President, Global Gene Therapy Business, Rare Disease, Pfizer 
Sonal Bhatia, Chief Medical Officer, Rare Disease, Pfizer

Our guest in this week's episode is Dr. Cristiano Façanaha, global director at environmental advocacy group CALSTART. He is a transportation and environmental engineer and an expert at designing and evaluating sustainable transportation systems. The world just concluded the COP26 climate conference in Scotland. Out of that meeting came several international initiatives and commitments to reduce carbon emissions. A couple of these directly affect the trucking and transportation sectors. Our guest addresses what they are and what they mean for the industry.

Consumers don't trust pharmaceutical supply chains. They worry about counterfeit medicines sneaking into their medicine cabinets as well as possible damage and contamination of genuine medicines as they travel throughout the supply chain. What can the industry do to assure our medicines are safe and to restore public confidence in them?

We have experienced tight freight capacity throughout this year, and it looks like it will continue well into 2022. A shortage of trucks and drivers, along with surging demand from the holiday season, will mean that rates will stay high and available capacity will not improve for the foreseeable future.

DC Velocity's sister publication CSCMP's Supply Chain Quarterly has  a new 11-episode limited podcast series called the Top 10 Supply Chain Threats. Each week, a different threat to our supply chains is discussed, including capacity constraints, labor shortages, inflation and economics, weather-related issues, component and product shortages, digitalization, automation, and much more. Subscribe at your favorite podcast platform. Search "Top 10 Supply Chain Threats."


Articles and resources mentioned in this episode:

• CALSTART's Global Drive to Zero
• Study highlights pharmaceutical supply chain problems
• FTR says trucking fleets will enjoy a strong market well into 2022
• Visit DCVelocity.com for the latest news. 
• Visit Supply Chain Quarterly
• Listen to Supply Chain Quarterly's Top 10 Supply Chain Threats podcast
• Send feedback about this podcast to podcast@dcvelocity.com.

Podcast sponsored by: Ryder

Other links

• About DC VELOCITY
• Subscribe to DC VELOCITY
• Sign up for our FREE newsletters
• Advertise with DC VELOCITY
• Top 10 Supply Chain Management Podcasts

As much as modern technology and science try to alleviate human suffering, the world has been plagued by numerous health problems afflicting the lives of people. Due to COVID-19, the rate of mortality increased resulting in widespread medical and economic challenges. 

Our body has interferon proteins that are part of the natural defenses. They work by interfering with the virus to enter the body by activating the body’s immune system. This is one of the first lines of defense the human body has when it gets infected with COVID-19 but unfortunately, this is not enough.

According to WHO, as of November 2021, there have been approximately 200 million confirmed cases of COVID-19. For COVID-19 medications, Remdesivir is one of the few drugs approved by the FDA to treat COVID-19 yet researchers are still evaluating which drug works best to fight the global pandemic.

In this episode, Dr. Dung Trinh is joined by Dr. Ajay Gupta, an inventor, and innovator who has investigated Ramatroban, new immunotherapy with a potential treatment for COVID-19. Though still under development, early-phase clinical trials and studies have been promising. 

Learn more about the potential of this medication in Episode 9!

Memorable Quotes:

• When there’s a new drug, it takes a lot of clinical trials to ensure that the drug is not just going to be effective but more importantly, it is going to be safe. - Dr. Ajay Gupta
• New medications for Covid have to undergo multiple phases of clinical trials but there isn’t always funding for these needed studies. - Dr. Dung Trinh

Other Resources:

• kidneydoc789@gmail.com - Dr. Ajay Gupta

Important Points:

• The severity of illness from COVID-19 infection depends on how the body reacts to the virus.
• As humans age, we produce more Prostaglandin d2 (PGD2). When infected with a virus, the production of PGD2 increases further and suppresses interferons - one of the first immune responders of the body.

About the Guest:

Ajay Gupta, MD is an inventor who currently develops Ramatroban, a PGD2-CRTH2 antagonist, immunotherapy for COVID-19. He is a nephrologist and basic and clinical scientist, the Section Head of Pediatric Epilepsy at Cleveland Clinic, currently the Clinical Professor of Medicine at University of California, Irvine - College of Medicine, and President and Chief Scientific Officer of KARE Biosciences, 

About the Host:

Dung Trinh, MD is the Chief Medical Officer of Irvine Clinical Research, medical missionary with TongueOut Medical Missions, and holds leadership positions with multiple healthcare organizations in Orange County. 

Connect with Dr. Trinh:

• Facebook
• LinkedIn
• YouTube

A Team Dklutr Production

Gene therapy is at a pivotal moment. For eligible rare disease patients, the potential impact could be huge. So how can we support that potential to fruition and what will it mean if we do? In our season finale, host Adam Rutherford and guests take a peek into what a world with successful gene therapies could look like for patients, healthcare and society.

Featuring guests:
Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare Disorders
Erik Paulsen, Chair, Institute for Gene Therapies
Karolina Hanslik, Former Senior Project Manager, EURORDIS
Nikhil Gadre, Senior Director, Global Commercial, Hemophilia Gene Therapy, Pfizer
Paige Bischoff, Senior Vice President, Global Public Affairs,  Alliance for Regenerative Medicine
Paolo Morgese, EU Director, Market Access, Alliance for Regenerative Medicine
Reda Guiha, IDM Regional President, Rare Disease, Pfizer
Simone Boselli, Director, Public Affairs, EURORDIS
Tomislav Sokol, Member of European Parliament

As with any new breakthrough medicine, entering the healthcare system comes with a host of obstacles and potential barriers. In this episode, Adam Rutherford and guests break down the big changes needed within the global healthcare ecosystem to ensure that, once approved, the therapies we’re researching now, like gene therapy, reach the patients who need them.

Featuring guests:
Bert Bruce, Regional President, North America, Rare Disease, Pfizer 
Brenda Cooperstone, Senior Vice President, Chief Development Officer, Rare Disease, Pfizer
Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare Disorders
Emily Crossley, Chief Executive Officer, Duchenne UK
Erik Paulsen, Chair, Institute for Gene Therapies
Karolina Hanslik, Senior Project Manager, EURORDIS
Katherine Beaverson, Senior Director and Patient Advocacy Lead, Rare Disease Research Unit, Pfizer
Nikhil Gadre, Senior Director, Global Commercial, Hemophilia Gene Therapy, Pfizer
Suneet Varma, Global President, Rare Disease, Pfizer
Tomislav Sokol, Member of European Parliament



 

Gene therapy has come a long way to get where it is today but there is still much to learn and investigate. Host Adam Rutherford speaks to a line-up of experts about the vital role of clinical trials and the unique challenges facing gene therapy and rare disease patients.

Featuring guests:
Brenda Cooperstone, Senior Vice President, Chief Development Officer, Rare Disease, Pfizer
Emily Crossley, Chief Executive Officer, Duchenne UK
Erik Paulsen, Chair, Institute for Gene Therapies
Professor John Rasko, Clinical Haematologist & Trial Investigator, University of Sydney
Simone Boselli, Director, Public Affairs, EURORDIS
Suneet Varma, Global President, Rare Disease, Pfizer

Gene therapy is a revolutionary field of science that has the potential to transform lives. It presents this big question; What if we could treat a disease at its root cause, rather than just the symptoms? On the first episode of Science Will Win, host Adam Rutherford takes us through the history, science, and significance of gene therapy.

Featuring guests:

Dirk Vander Mijnsbrugge, Vice President, Medical Affairs, Rare Diseases, Pfizer
Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare Disorders
Laurence Woollard, Director, On The Pulse Consultancy
Sonal Bhatia, Chief Medical Officer, Rare Disease, Pfizer

You can say hello to Berty at

A weekly podcast to help you appear smarter, to an audience that knows no less! Your four hosts - Chuck, Naren, Srikeit and Tony attempt to deconstruct topics with humour (conditions apply). Fans of the show have described it as "fun conversations with relatable folks", "irreverent humour", "the funniest thing to come out of Malad West" and "if I give you a good review will you please let me go".

You can contact the hosts on:

See omnystudio.com/listener for privacy information.

Science Will Win explores the fascinating science, policy, and humanity which is shaping the future of healthcare and transforming patients’ lives for the better. 

Hosted by Adam Rutherford, geneticist and Honorary Fellow at University College London, our first miniseries takes listeners on a journey behind the science of gene therapy; the next generation of medicines bringing new possibilities for patients living with rare genetic diseases. 

At a time when innovative science is achieving the seemingly impossible, we’ll look at gene therapy from every angle, speaking to scientists and experts on the forefront of medical research, as well as the patients and families who are holding new hope in the life-changing potential of gene therapy. 

In this episode, our guest is Dr. Emily Tucker, assistant professor at Clemson University's Department of Industrial Engineering. Most of the medicines we rely on every day come from just two key trading partners overseas. That has created shortages and vulnerabilities in our medical supply chains and has limited our abilities to assure that we have medicines when we need them. Dr. Tucker explains why we have this problem and what can be done to solve it.

Ocean going vessels make up a significant portion of the carbon released into the atmosphere. This week we learned that Maersk, the huge container shipping company, is taking steps to decarbonize its operations. In an announcement Maersk says it has ordered a large16,000 TEU cargo vessel that will be carbon neutral. This new vessel will be powered by methanol. Is this a step in helping to alleviate climate change?

Susan Lacefield, the executive editor of CSCMP's Supply Chain Quarterly joins us to discuss the State of Logistics special issue. This issue of the Quarterly takes a deep dive into major aspects of logistics with specific articles on the status of freight, parcel, rail, air, ocean, inventory, and other market segments. How does the industry look now and how might that change in the near term?


Articles and resources mentioned in this episode:

• Clemson University's Department of Industrial Engineering
• Maersk to take delivery of carbon-neutral container ships in 2024
• Will logistics' wild ride continue?
• Supply Chain Quarterly website
• Visit DCVelocity.com for the latest news. 
• Send feedback about this podcast to podcast@dcvelocity.com.

Podcast sponsored by: Softeon

Other links

• About DC VELOCITY
• Subscribe to DC VELOCITY
• Sign up for our FREE newsletters
• Advertise with DC VELOCITY
• Top 10 Supply Chain Management Podcasts

Not a boring podcast, I assure you!  You'll hear a couple of stories of ways I've prevented some health issues while traveling, and a few ideas I've come up with along travel journeys! 

Good or bad, we have our health, at home or traveling.  Let's take advantage of some helpful tips to keep our travel good while on the road or in the air.

What changes can we expect to pharmacy, medicines management, and specialised commissioning in the new NHS?  Professor Inderjit Singh (Chief Pharmacist at University Hospitals Birmingham) joins Tom Clarke (Director, Mtech Access) to explore all this and more.

Professor Singh is one of the leading pharmacists in today’s NHS and is currently Chief Pharmacist at University Hospitals Birmingham NHS Foundation Trust. He has responsibility for the provision of the pharmacy service within the Trust and for ensuring appropriate governance of medicines. He provides strategic oversight into commercial pharmacy matters and strategic support to Heath Trust Europe, a collaborative procurement hub based in Birmingham.

This episode was first broadcast as a live webinar on Friday 26th March 2021.

Learn more about our NHS insights services at: https://mtechaccess.co.uk/uk-nhs-insights/ 

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

Colonel (ret) Dr. Geoffrey Ling, MD, PhD is the Founder and CEO of On Demand Pharmaceuticals (ODP), an innovative pharmaceutical manufacturing company creating the world’s first distributed and reconfigurable medicine production systems to enable rapid response when conditions are uncertain and changing. On Demand Pharmaceuticals mission is to provide an adequate, safe, and reliable supply of medicines, to any community across the world, when needed. In addition to his role as CEO at On Demand Pharmaceuticals, Dr. Ling is an attending neuro-intensive care physician and Professor of Neurology at Johns Hopkins, Director of the Neurotrauma Laboratory, and founder of the Center for Military Clinical Neurosciences at the Uniformed Services University of the Health Sciences (USUHS). Dr. Ling is also the former founding Director of the Biological Technologies Office at DARPA. Dr. Ling is Vice-Chair of Research in the Department of Clinical Neurosciences at Inova Fairfax Medical Center, Fairfax, VA, where he provides leadership for the research programs in neurosurgery, neurology and physical medicine rehabilitation. Dr. Ling earned his PhD in Pharmacology at Cornell University Graduate School of Medical Sciences, and his MD at Georgetown University School of Medicine. 

With new policy passing power to Integrated Care Systems (ICS), we explore how pharmacy and medicines commissioning will work in the new system, with Laura Angus (Interim Lead Pharmacist, Humber, Coast and Vale ICS)

In our December #WhispersWordsofWisdom webinar, Tom Clarke was joined by Laura Angus who, in her new appointment as a Lead Pharmacist in an Integrated Care System (ICS), is currently evaluating the impact of the transfers of budget and decision-making power from Clinical Commissioning Groups (CCGs) to an ICS. Her appointment as Interim Lead Pharmacist at Humber Coast and Vale ICS in November, follows 7-years as Head of Prescribing at NHS Vale of York CCG.

Laura shares her frontline insights into the structural changes in the NHS, and what this means for pharmacy and the role of medicines.

This episode was originally broadcast on 15th December 2020 as a webinar.

Learn more about our NHS insights services at: https://mtechaccess.co.uk/uk-nhs-insights/ 

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

Hypoestrogenism refers to lower than normal levels of estrogen in our body. This is a normal physiologic response in postmenopausal women but is a concerning find in women trying to conceive. Although less common than low progesterone, hypoestrogenism requires proper diagnosis and treatment to prevent long-term health consequences.

_______________

In this difficult time of COVID-19, We understand how frustrating it gets while dealing with infertility. Please don't stress yourself, just take care, stay at home, stay active, stay healthy and stay fertile, surround yourself with some positive news or vibes than just listening to COVID-19 news.

We also teach Fertility charting, the sessions are delivered online which help you to track ovulation and periods date. Ovulation tracking via fertility charting is about 98% effective than a usual ovulation calendar or normal period calendar app. Achieve faster results and healthy pregnancy with our natural family planning course (nature's way to get pregnant).

If you struggling to conceive or just planning to conceive or planning for IVF contact our fertility advisor we have designed a special programme which is focused on you to have a healthy pregnancy, alongside it also help you to have a healthy lifestyle, enhance & nurture the relationship with your partner. Contact details are given below:

____________________________

If you think that this podcast has been helpful then please do take a minute to show your love and support by rating this podcast in below link

https://ratethispodcast.com/fertilityed

If you have any other question regarding this podcast or if you want us to address any particular topic you can always email us at

info@fertilityed.com

Website: https://www.fertilityed.com

Instagram: https://www.instagram.com/fertilityeducation

Facebook: https://www.facebook.com/FertilityEd

To get support and expert advice on your fertility journey contact us at:

clinic@origenfertility.com

www.origenfertility.com

https://www.instagram.com/origenfertility/